Full-Time
Associate Director
Data Product Management
Posted on 6/6/2026
Amgen
10,001+ employees
Biotech company creating biologic medicines
No salary listed
Hyderabad, Telangana, India
In Person
 Product (1) |
|---|
- 16 to 20 years of experience in Information/Tech Systems
- Execute and scale the global Data & Digital Product Management capability across India-based teams.
- Embed global product management, agile, and performance standards into day-to-day execution.
- Drive consistency in outcomes, delivery quality, and ways of working across portfolios.
- Provide structured feedback and insights from India teams to inform global capability evolution.
- Lead and develop managers and senior individual contributors across productmanagement,agile delivery, andbusinessperformance functions.
- Build a strong leadership bench with clear role clarity, accountability, and growth paths.
- Own hiring, onboarding, performance management, and talent development for India-based teams.
- Foster a high-performance, collaborative culture aligned with global expectations.
- Build and sustain trusted partnerships with India- and U.S.-based senior stakeholders, shaping alignment on priorities, trade-offs, and delivery outcomes.
- Lead proactive communication and change efforts to driveadoptionof evolving product, agile, and business performance operating models.
- Act as the senior EDSE India representative in leadership forums and site visits, confidently articulating progress, risks, and impact while modeling Amgen values.
- Provide leadership oversight acrossProduct Management,AgilePMOand Business Performance functions in partnership with Senior Managers.
- Ensure integrated planning, delivery tracking, and performance insights across portfolios.
- Maintain executive-level visibility into progress, risks, and outcomes.
- 8+ years in senior leadership roles leading managers and multi-disciplinary teams.
- Experience operating in a global capability, shared services, or matrixed delivery model.
- Strong background working with product, data, and technology teams.
- Familiarity with Agile/SAFe operating models and portfolio-level delivery governance.
- Proven ability to partner with senior leaders across regions and influence without direct authority.
- Experience in data, digital, AI, or advanced analytics environments; life sciences experience is a plus.
- Strong balance of strategic thinking and willingness to roll up sleeves when needed.
- Confident and clear communicator who builds trust quickly.
- Effective at balancing structure with flexibility in dynamic environments.
- Team-first mindset with a commitment to shared success.
Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.
Company Size
10,001+
Company Stage
IPO
Headquarters
Thousand Oaks, California
Founded
1980
Simplify's Take
What believers are saying
- MariTide's four-to-six-dose regimen could improve adherence and support obesity launch uptake.
- IMDYLLTRA's Phase 3 survival benefit strengthens Amgen's oncology pipeline and commercial credibility.
- Repatha growth, strong free cash flow, and AI efficiency support margin expansion.[1]
What critics are saying
- Prolia's declining sales expose Amgen to erosion in its mature osteoporosis franchise.
- MariTide still faces Phase 3, manufacturing, and tolerability execution risk before launch.
- Tavneos regulatory scrutiny and tarlatamab safety concerns can limit near-term revenue conversion.
What makes Amgen unique
- Amgen spans oncology, inflammation, rare disease, and general medicine across 100 countries.[1][3]
- It combines biologics manufacturing with AI-driven discovery and development workflows.[1][5]
- MariTide and IMDYLLTRA give Amgen distinct obesity and small-cell lung cancer growth options.[1]
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Amgen who can refer or advise you
Benefits
Professional Development Budget
Conference Attendance Budget
Company News
Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.
Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.
Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.
Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.
Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.